Genome Therapeutics Prices Stock Offering at $5.25 per Share | GenomeWeb

NEW YORK, Feb. 3 (GenomeWeb News) - Genome Therapeutics has set a price of $5.25 per share for the sale of up to 16.8 million shares of its common stock, the company said today.

The offering will fund the pending acquisition of Genesoft Pharmaceuticals, which was approved by the shareholders of both firms yesterday. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.